APOE and early-onset autosomal dominant Alzheimer disease: As over 50% of APOE ε4 carriers do not develop clinical Alzheimer’s disease, longitudinal studies are clearly required to determine whether APOE ε4, coupled with disrupted DHA absorption to the brain, has diagnostic utility, and can predict conversion to clinical Alzheimer’s disease with a high degree of accuracy.54